Literature DB >> 3585290

Standardization of a plaque assay for Lassa virus.

O Tomori, K M Johnson, M P Kiley, L H Elliott.   

Abstract

The plaque reduction neutralization test (PRNT) has been used routinely in serological studies with such arenaviruses as Junin, Machupo, and Parana. However, difficulties have been encountered in using the PRNT for LCM virus, while conflicting views have been expressed about the reliability and efficacy of the test with Lassa virus. We have therefore investigated and evaluated the plaque assay for Lassa virus. In addition, the suitability of the PRNT for determining the potency of a serum and its efficacy in passive immunization for the treatment of Lassa fever was also investigated. The Lassa virus plaque assay satisfied the criteria proposed by Cooper [1961] for determining satisfactory plaque technique. Lassa virus plaques appear within 3 days of inoculating Vero cell cultures. By day 5, the plaques are clearly defined, discrete, and measure 1.5 to 2.0 mm. In the plaque reduction neutralization test, the use of native non-inactivated serum was required for a reliable and reproducible determination of serum antibody titer. The potency and suitability of a serum for Lassa fever serotherapy was determined by the use of a constant serum-varying virus (CS-VV) and/or a constant virus-varying serum (CV-VS) PRN technique.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3585290     DOI: 10.1002/jmv.1890220110

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  9 in total

1.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

2.  Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein.

Authors:  J ter Meulen; M Badusche; K Kuhnt; A Doetze; J Satoguina; T Marti; C Loeliger; K Koulemou; L Koivogui; H Schmitz; B Fleischer; A Hoerauf
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

3.  Characterization of Lassa virus cell entry and neutralization with Lassa virus pseudoparticles.

Authors:  François-Loic Cosset; Philippe Marianneau; Geraldine Verney; Fabrice Gallais; Noel Tordo; Eve-Isabelle Pécheur; Jan ter Meulen; Vincent Deubel; Birke Bartosch
Journal:  J Virol       Date:  2009-01-19       Impact factor: 5.103

4.  Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.

Authors:  Kathleen A Cashman; Mark A Smith; Nancy A Twenhafel; Ryan A Larson; Kevin F Jones; Robert D Allen; Dongcheng Dai; Jarasvech Chinsangaram; Tove' C Bolken; Dennis E Hruby; Sean M Amberg; Lisa E Hensley; Mary C Guttieri
Journal:  Antiviral Res       Date:  2011-03-01       Impact factor: 5.970

5.  Envelope exchange for the generation of live-attenuated arenavirus vaccines.

Authors:  Andreas Bergthaler; Nicolas U Gerber; Doron Merkler; Edit Horvath; Juan Carlos de la Torre; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2006-06-02       Impact factor: 6.823

6.  Calcium Regulation of Hemorrhagic Fever Virus Budding: Mechanistic Implications for Host-Oriented Therapeutic Intervention.

Authors:  Ziying Han; Jonathan J Madara; Andrew Herbert; Laura I Prugar; Gordon Ruthel; Jianhong Lu; Yuliang Liu; Wenbo Liu; Xiaohong Liu; Jay E Wrobel; Allen B Reitz; John M Dye; Ronald N Harty; Bruce D Freedman
Journal:  PLoS Pathog       Date:  2015-10-29       Impact factor: 6.823

7.  A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.

Authors:  Kathleen A Cashman; Eric R Wilkinson; Carl I Shaia; Paul R Facemire; Todd M Bell; Jeremy J Bearss; Joshua D Shamblin; Suzanne E Wollen; Kate E Broderick; Niranjan Y Sardesai; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2017-10-18       Impact factor: 3.452

Review 8.  Serological assays based on recombinant viral proteins for the diagnosis of arenavirus hemorrhagic fevers.

Authors:  Shuetsu Fukushi; Hideki Tani; Tomoki Yoshikawa; Masayuki Saijo; Shigeru Morikawa
Journal:  Viruses       Date:  2012-10-12       Impact factor: 5.048

Review 9.  The Role of Nucleoprotein in Immunity to Human Negative-Stranded RNA Viruses-Not Just Another Brick in the Viral Nucleocapsid.

Authors:  Maja Šantak; Zrinka Matić
Journal:  Viruses       Date:  2022-03-03       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.